Get the Stockscreener App
0.278
13.48%
-0.0433
After Hours:
.29
0.012
+4.32%
Reviva Pharmaceuticals Holdings Inc stock is traded at $0.278, with a volume of 14.54M.
It is down -13.48% in the last 24 hours and down -47.39% over the past month.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
See More
Previous Close:
$0.3213
Open:
$0.291
24h Volume:
14.54M
Relative Volume:
1.42
Market Cap:
$31.99M
Revenue:
-
Net Income/Loss:
$-27.11M
P/E Ratio:
-0.4277
EPS:
-0.65
Net Cash Flow:
$-26.55M
1W Performance:
-54.88%
1M Performance:
-47.39%
6M Performance:
-65.46%
1Y Performance:
-84.38%
1-Day Range:
$0.25
$0.31
1-Week Range:
$0.25
$0.6678
52-Week Range:
$0.25
$2.17
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Name
Reviva Pharmaceuticals Holdings Inc
Sector
Industry
Phone
(408) 501-8881
Address
10080 N WOLFE ROAD, CUPERTINO
Compare RVPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.278 | 36.97M | 0 | -27.11M | -26.55M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Sep-20-23 | Initiated | ROTH MKM | Buy |
| Jun-08-23 | Initiated | The Benchmark Company | Speculative Buy |
| Jan-24-22 | Initiated | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News
Is Nagreeka Exports Limiteds Business Model Sustainable Long Term - earlytimes.in
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025 - ts2.tech
Reviva Pharmaceuticals' (RVPH) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Reviva Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - MarketBeat
FDA recommends second phase 3 trial for Reviva’s schizophrenia drug By Investing.com - Investing.com Nigeria
Reviva considers a second phase III in schizophrenia - BioWorld MedTech
Dow Gains 100 Points; US Durable Goods Orders Decline In October - Benzinga
Why Did RVPH Stock Crash 50% Today? - Stocktwits
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug - Benzinga
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial - Investing.com Australia
Reviva Pharmaceuticals stock plunges after FDA requests second Phase 3 trial By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Reviva plans second Phase 3 trial after FDA feedback - TipRanks
Reviva announces regulatory update regarding the development of brilaroxazine for the treatment of schizophrenia - marketscreener.com
Reviva Pharmaceuticals Recover-2 trial projected to cost about $60 million - marketscreener.com
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia - GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock maintain growth trajectory2025 Fundamental Recap & Reliable Breakout Forecasts - Улправда
Profit Recap: Why Reviva Pharmaceuticals Holdings Inc. stock could benefit from AI revolutionIPO Watch & Smart Swing Trading Techniques - Улправда
Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue dividend increasesTrade Performance Summary & Long-Term Safe Investment Plans - Улправда
Volatility Watch: Why Reviva Pharmaceuticals Holdings Inc. stock could benefit from AI revolutionTrade Exit Report & Low Risk Entry Point Tips - Улправда
Does Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock trade at a discount to peersPortfolio Value Summary & Risk Controlled Stock Alerts - Улправда
Why Reviva Pharmaceuticals Holdings Inc. stock could benefit from AI revolutionWeekly Investment Report & Capital Efficiency Focused Ideas - Улправда
Will Reviva Pharmaceuticals Holdings Inc. stock attract ESG investorsNew Guidance & Capital Protection Trading Alerts - DonanımHaber
Resistance Check: Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trend2025 Key Highlights & Weekly High Momentum Picks - Улправда
Why retail investors favor Reviva Pharmaceuticals Holdings Inc. stockIPO Watch & Safe Entry Zone Tips - DonanımHaber
Can Reviva Pharmaceuticals Holdings Inc. stock resist market sell offsMarket Risk Analysis & Daily Volume Surge Trade Alerts - DonanımHaber
Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trendWeekly Market Summary & Pattern Based Trade Signal System - Улправда
What makes Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock attractive to growth fundsJuly 2025 Momentum & Consistent Return Investment Signals - DonanımHaber
Can Reviva Pharmaceuticals Holdings Inc. stock sustain institutional interestWeekly Risk Report & Real-Time Market Sentiment Alerts - Улправда
Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefit from automation2025 Trading Volume Trends & Weekly Hot Stock Watchlists - Улправда
Block Trades: Can Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock continue upward trendEarnings Growth Report & Fast Moving Stock Watchlists - Улправда
Profit Recap: Will Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock benefit from automationShare Buyback & Weekly Stock Performance Updates - Улправда
Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High - Seeking Alpha
Reviva Pharmaceuticals Holdings Inc Stock Analysis and ForecastMarket Depth Overview & Swing Trade Smarter With Data Insights - earlytimes.in
683 Capital Management LLC Makes New Investment in Reviva Pharmaceuticals Holdings, Inc. $RVPH - Defense World
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025 - ts2.tech
Stock Traders Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH) - MarketBeat
Published on: 2025-12-06 19:16:30 - moha.gov.vn
How supply chain issues affect Reviva Pharmaceuticals Holdings Inc. Equity Warrant stockWeekly Investment Summary & Accurate Buy Signal Alerts - Newser
Largest borrow rate increases among liquid names - TipRanks
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Are Smart Investors Making the Right Decision? Reviva Pharmaceuticals Holdings Inc (RVPH) - setenews.com
Is RVPH Positioned For NDA Submission In Schizophrenia By 2026? - RTTNews
Reviva Pharmaceuticals Holdings options imply 21.1% move in share price post-earnings - MSN
Reviva’s Schizophrenia Bet Pits Huge Upside Against Harsh Risks - Finimize
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
EBIT per share of Reviva Pharmaceuticals Holdings, Inc. Warrant 2020- 25.12.25 on Reviva Pharm – NASDAQ:RVPHW - TradingView
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):